United States: DC Metro Area Robert D Litowitz

Partner - Kelly IP LLP

Robert D Litowitz is an outstanding strategist, persuasive writer and advocate who distills complex facts and issues into winning themes and narratives. Mr Litowitz’s litigation experience includes trademark cases before the courts and the Trademark Trial and Appeal Board, false advertising, unfair competition, design patent, copyright and trade secret cases. He has worked extensively with leading experts to develop and present consumer surveys. Mr Litowitz has also litigated patent cases on products ranging from blockbuster prescription drugs to state-of-the-art jet engines. At both the trial and appellate level, Mr Litowitz has secured wins for household brands and lifesaving medicines.

He has been recognised locally and internationally as a leading IP litigator and trademark practitioner. Mr Litowitz achieved silver status for enforcement and litigation in the Washington DC area by the WTR 1000 (2016). He has been recognised by Managing Intellectual Property as an IP Star (2014-2015), as a recommended trademark lawyer by The Legal 500 (2014), as among the top legal practitioners in trademark law in the US by Legal Media Group's Expert Guides: Guide to the World's Leading Trade Mark Lawyers and as one of the best IP lawyers (2011-2013) by the Washingtonian.

He currently serves as a member of the International Trademark Association’s committee on famous marks. Before joining Kelly IP, Mr Litowitz practised all aspects of IP law for 26 years at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP in Washington DC. He was a partner there for 20 years and served on the firm’s management and compensation committees.

Firm details

Kelly IP LLP
1919 M Street NW
Suite 610
Washington DC 20036
United States

Contact details

E: robert.litowitz@kelly-ip.com
T: +1 202 808 3572
F: +1 202 354 5232
W: www.kelly-ip.com

Related articles

Procedures and strategies for pharmaceutical brands: United States
Pharmaceutical Trademarks 2017/2018: A Global Guide

Drug makers face unique challenges when selecting and clearing trademarks for new drugs. Care must be taken to select a name that can be registered at the US Patent and Trademark Office (USPTO) and will meet the Food and Drug Administration’s (FDA) stringent approval process. USPTO ...

Close

Register for more free content

  • Read more World Trademark Review blogs and articles
  • Receive the editor's weekly review by email
Register now  
Issue 70